AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Arcturus Therapeutics to Present at Upcoming Investor Conference

January 6, 2021 GMT

SAN DIEGO--(BUSINESS WIRE)--Jan 6, 2021--

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13 th Annual Biotech Showcase™ Investor Conference:

Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace

ADVERTISEMENT

  • Panel Discussion
  • Date: Monday, Jan 11, 2020
  • Time: 1:00 p.m. ET, on-demand Jan 12-March 31 on the event’s platform, partneringONE
  • Conference Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (205 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20210106005325/en/

CONTACT: IR and Media ContactsArcturus Therapeutics

Neda Safarzadeh

(858) 900-2682

IR@ArcturusRx.comKendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

ctanzi@kendallir.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: GENERAL HEALTH HEALTH SCIENCE PHARMACEUTICAL RESEARCH

SOURCE: Arcturus Therapeutics Holdings Inc.

Copyright Business Wire 2021.

PUB: 01/06/2021 08:00 AM/DISC: 01/06/2021 08:01 AM

http://www.businesswire.com/news/home/20210106005325/en